브리바라세탐
|
|
브리바라세탐 속성
- 녹는점
- 76.38°
- 알파
- D25 -60.57° (c = 1 in methanol)
- 끓는 점
- 409.3±28.0 °C(Predicted)
- 밀도
- 1.062
- 저장 조건
- Refrigerator
- 용해도
- DMSO(약간 용해됨), 메탄올(약간 용해됨)
- 물리적 상태
- 고체
- 물리적 상태
- 단단한 모양
- 산도 계수 (pKa)
- 15.74±0.50(Predicted)
- 색상
- 흰색에서 황백색까지
- InChI
- InChI=1/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/s3
- InChIKey
- MSYKRHVOOPPJKU-MASDURLHNA-N
- SMILES
- [C@H](N1C(C[C@@H](CCC)C1)=O)(CC)C(=O)N |&1:0,4,r|
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
브리바라세탐 C화학적 특성, 용도, 생산
개요
Brivaracetam, a novel oral antiepileptic drug with a high affinity for synaptic vesicle protein 2A (SV2A), was approved in Europe and the US as an adjunctive therapy for the treatment of partial onset seizures with or without secondary generalization in patients aged 16 or older.42 Brivaracetam is very closely related to levetiracetam, an antiepileptic treatment whose immediate release formulation has been available in the United States as a generic drug since 2008, but whose extended release formulation is under patent protection until 2028. The two drugs, which were both developed by UCB Pharma, are structurally similar with brivaracetam having an n-propyl group at the C-4 position of the pyrrolidinone ring and levetiracetam having a hydrogen at this same position. A systematic investigation of the various substitutions of levetiracetam resulted in the identification of more potent and selective SV2A ligands and ultimately culminated in the discovery of brivaracetam, which has greater affinity for SV2A, improved selectivity, more rapid brain penetration, and faster onset of action against seizures than levetiracetam.용도
Treatment ofTreatment of epilepsy, neuropathic pain and essential tremor.정의
ChEBI: A non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy.부작용
Common side effects of brivaracetam include: constipation, nausea, vomiting, extreme tiredness or low energy. Serious side effects that may be caused include: swelling of the face, throat, tongue, lips, and eyes; difficulty swallowing or breathing; hoarseness, hallucinations (seeing things or hearing sounds that are not there), and delusions (strange thoughts or beliefs that have no basis in reality). An overdose may cause: drowsiness, extreme tiredness, dizziness, difficulty maintaining balance, blurred or double vision, slowed heartbeat, nausea, and feeling anxious.브리바라세탐 준비 용품 및 원자재
원자재
준비 용품
브리바라세탐 공급 업체
글로벌( 325)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Chengdu Aupone Pharmaceutical Co.Ltd. | +86-28-+86-28-87843998-6060-6060 +8618631098571 |
lijiaqi@aupone.com | China | 43 | 58 |
Lewoo Pharmatech(Shanghai)Co.,Ltd | +86-15800805830 +86-15800805830 |
miao@lewoopharma.com.cn | China | 156 | 58 |
Biopole Pharmatech Co., Ltd. | +8615151475053 |
biopole@163.com | China | 37 | 58 |
Dorne Chemical Technology co. LTD | +86-13583358881 +86-18560316533 |
Ethan@dornechem.com | China | 290 | 58 |
Firsky International Trade (Wuhan) Co., Ltd | +8615387054039 |
admin@firsky-cn.com | China | 436 | 58 |
shandong perfect biotechnology co.ltd | +86-53169958659; +8618596095638 |
sales@sdperfect.com | China | 294 | 58 |
Wuhan Ruichi Technology Co., Ltd | +8613545065237 |
admin@whrchem.com | China | 164 | 58 |
Shandong Hanjiang Chemical Co., Ltd | +86-0533-2066820 +8618369939125 |
hanson@sdhanjiang.com | China | 1527 | 58 |
Shanghai Affida new material science and technology center | +undefined15081010295 |
2691956269@qq.com | China | 349 | 58 |
Nanjing Gold Pharmaceutical Technology Co. Ltd. | 025-84209270 15906146951 |
CHINA | 115 | 55 |
브리바라세탐 관련 검색:
Dihydro-4-propyl-2(3H)-furanone
Atorvastatin
Brivaracetam (alfaR, 4R)-Isomer
Brivaracetam (alfaR, 4S)-Isomer
(R)-2-(2-(tert-butoxy)-2-oxoethyl)pentanoic acid
(4S)-BrivaracetaM
tert-butyl (R)-3-(hydroxymethyl)hexanoate
Brivaracetam (Racemate)
Sumatriptan
Deferasirox
Fosaprepitant dimeglumine
IXABEPILONE
Brivaracetam Impurity 21
(Z)-2-propylhept-2-enal
Brivaracetam-d7
(R)-4-Propyldihydrofuran-2(3H)-one
Brivaracetam
brivaracetam intermediate 3